Pricing Log in Create free account

Cellyan Biotechnology Co., Ltd (HKPD) vs Henry Schein, Inc. (HSIC)

Cellyan Biotechnology Co., Ltd and Henry Schein, Inc. are both Medical Distribution companies. Henry Schein, Inc. is the larger, with a market value of $9.4B against $3.4M — 2814.9× the size. Across the 10 metrics below, Henry Schein, Inc. leads on 6 and Cellyan Biotechnology Co., Ltd on 4.

Valuation

Metric HKPD HSIC Medical Distribution median
P/E — 22.76 —
P/S — 0.69 0.27
P/B n/m 2.49 —
Price to free cash flow n/m 17.00 —
EV/EBITDA n/m 11.38 17.33
EV/Sales n/m 0.86 0.86
Earnings yield — 4.39% (13.85%)
Free cash flow yield 0.00% 5.88% (6.11%)

Profitability

Metric HKPD HSIC Medical Distribution median
Gross margin — 31.59% 5.74%
Operating margin — 5.16% 0.00%
Net margin — 3.07% (11.41%)
Free cash flow margin 0.00% 4.07% (0.36%)
Return on equity 0.00% 10.74% 0.00%
Return on assets 0.00% 3.72% (1.95%)
Return on invested capital 0.00% 7.20% 0.00%

Growth

Metric HKPD HSIC Medical Distribution median
Revenue growth (TTM) — 6.15% 6.15%
EPS growth (last fiscal year) (2,521.89%) 7.21% 5.18%
Revenue growth, 5-year CAGR — 5.43% 8.18%
Net income growth, 5-year CAGR 0.00% (0.30%) 0.00%

Health

Metric HKPD HSIC Medical Distribution median
Debt to equity 0.10 0.66 (0.66)
Current ratio 3.86 1.33 0.99
Net debt to EBITDA (0.79) 2.27 (0.10)

Dividend

Metric HKPD HSIC Medical Distribution median
Dividend yield — — —
Payout ratio — — —

Size

Metric HKPD HSIC Medical Distribution median
Market cap 3.35m 9.43b 97.81m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack